Pfizer Inc. $PFE Stock Position Increased by CX Institutional

Key Points

• CX Institutional increased its position in Pfizer by 50.6%, owning 47,032 shares valued at $1.14 million as of its latest SEC filing.
• A total of 68.36% of Pfizer's stock is owned by institutional investors, with multiple funds acquiring new positions recently.
• Pfizer reported an earnings per share of $0.78 for the last quarter, exceeding estimates and resulting in a revenue of $14.65 billion.

CX Institutional grew its position in Pfizer Inc. (NYSE:PFE - Free Report) by 50.6% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 47,032 shares of the biopharmaceutical company's stock after purchasing an additional 15,797 shares during the period. CX Institutional's holdings in Pfizer were worth $1,140,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in PFE. GKV Capital Management Co. Inc. acquired a new position in Pfizer during the 1st quarter worth $27,000. Bayforest Capital Ltd acquired a new stake in Pfizer in the first quarter worth about $28,000. North Capital Inc. acquired a new position in Pfizer during the 1st quarter valued at about $28,000. WPG Advisers LLC acquired a new position in Pfizer during the 1st quarter valued at about $35,000. Finally, Horizon Financial Services LLC acquired a new stake in shares of Pfizer in the 1st quarter worth approximately $35,000. Institutional investors own 68.36% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the stock. Wall Street Zen upgraded shares of Pfizer from a "hold" rating to a "buy" rating in a research note on Saturday, September 20th. Bank of America boosted their price objective on Pfizer from $27.00 to $28.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 6th. Berenberg Bank decreased their target price on Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a research note on Thursday, May 29th. Citigroup boosted their price target on shares of Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 6th. Finally, Morgan Stanley upped their price target on shares of Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a report on Wednesday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Pfizer currently has an average rating of "Hold" and a consensus price target of $28.12.

Pfizer Price Performance

NYSE PFE opened at $23.61 on Friday. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $30.43. The stock's 50-day moving average price is $24.57 and its two-hundred day moving average price is $24.16. The company has a market cap of $134.25 billion, a PE ratio of 12.56, a PEG ratio of 0.78 and a beta of 0.55. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.20. The business had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm's quarterly revenue was up 10.3% compared to the same quarter last year. During the same period last year, the firm posted $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.